Turnstone Biologics is hoping to buck a difficult trend in the research world of oncolytic viruses and cancer vaccines by using a combined and systemic approach to create a truly next-generation therapy in immuno-oncology.
Because proteins move constantly inside cells, Relay’s A-list founders and investor Third Rock Ventures think showing motion will reveal new ways to treat diseases. The first step is to go after the many frequently mutated oncogenes the industry is yet to drug.
PsiOxus thinks it has figured out how to systemically deliver viruses that only replicate in tumor cells. That turned heads at Bristol-Myers Squibb, which struck two deals with PsiOxus last year and provided a launchpad for a pipeline that uses viruses to directly kill cancer cells.